数字化疗法治疗弱视的成本-效果分析
该成本-效用分析基于已发表的随机对照试验数据,比较Luminopia、CureSight与眼镜、阿托品滴眼液、遮盖等常用弱视疗法的成本-效用。结果显示Luminopia与CureSight在既定支付意愿阈值下具有成本效益,对无法耐受遮盖或阿托品惩罚治疗者尤其可提供可行治疗选择。
要点
- 12周Luminopia治疗每获得1个QALY的成本为618美元,12周CureSight为368或427美元,16周CureSight为314或354美元(P<0.05)。
- 12周单纯眼镜治疗每获得1个QALY的成本为427美元,遮盖为101美元,16周阿托品为151美元。
- 12周治疗每获得1 log arcsec立体视改善的成本:眼镜6421美元、遮盖1801美元、CureSight 3007或3488美元。
核心结论
- 与既定支付意愿阈值相比,Luminopia或CureSight治疗弱视具有成本效益,可提供可行治疗选择,尤其适用于无法耐受遮盖或阿托品惩罚治疗者。
- 基于视力增益的Luminopia与CureSight成本效益值相当。
研究设计与样本
- 基于已发表随机对照试验数据的成本分析,数据来自Luminopia、CureSight和阿托品随机对照试验。
- 采用既往文献中基于患者偏好的时间权衡效用值进行成本-效用分析,检查费用依据报销数据计算,设备费用由Luminopia和CureSight销售代表提供。
- 所有治疗均包含眼镜费用,视力和立体视结局从阿托品、Luminopia和CureSight的随机对照试验外推。
- 质量调整生命年(QALY)通过将与视力增益相关的效用增益乘以获益持续时间计算。
主要发现
- 单纯眼镜治疗12周的费用为514美元,遮盖治疗12周为540美元,阿托品治疗16周为652美元,而Luminopia或CureSight治疗12周的费用分别为1951美元和1564或1814美元。
- 单纯眼镜或遮盖治疗12周每获得1个QALY的成本分别为427美元和101美元,阿托品治疗16周为151美元。
- 12周Luminopia治疗每获得1个QALY的成本为618美元,12周CureSight为368或427美元,16周CureSight为314或354美元(P<0.05)。
- 12周治疗每获得1 log arcsec立体视改善的成本:眼镜6421美元、遮盖1801美元、CureSight 3007或3488美元。
临床怎么用
- 作者认为,与既定支付意愿阈值相比,Luminopia或CureSight治疗弱视具有成本效益,可提供可行治疗选择,尤其适用于无法耐受遮盖或阿托品惩罚治疗者。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate the cost-utility of Luminopia (Luminopia, Inc) and CureSight (NovaSight, Ltd) as therapy for amblyopia compared with current common amblyopic treatments such as glasses, atropine drops, and patching. DESIGN: Cost analysis based on data from published randomized control trials (RCTs). SUBJECTS: Data from Luminopia, CureSight, and atropine RCTs. METHODS: A cost-utility analysis was performed using patient preference-based time trade-off utility values from previous literature. Costs for eye examinations were calculated using reimbursement data; device costs for duration of treatment were provided by sales representatives of Luminopia and CureSight. All treatments were inclusive of the cost of eyeglasses. Visual acuity (VA) and stereoacuity outcomes were extrapolated from the RCTs for atropine, Luminopia, and CureSight. A quality-adjusted life-year (QALY) was calculated by multiplying utility gain, a value correlated with VA gain, by length of time of benefit. MAIN OUTCOME MEASURES: Cost, cost per QALY, and cost per stereoacuity gain. RESULTS: The cost to treat amblyopia with glasses alone for 12 weeks was $514. The cost of treating with patching for 12 weeks was $540 and with atropine for 16 weeks was $652, whereas the cost of treating with Luminopia or CureSight for 12 weeks was $1951 and $1564 or $1814, respectively. Treatment with glasses alone or patching for 12 weeks resulted in a cost per QALY gained of $427 and $101, respectively. Atropine treatment for 16 weeks resulted in a cost per QALY gained of $151. The cost per QALY for 12-week Luminopia treatment was $618 versus $368 or $427 for 12-week CureSight treatment and $314 or $354 for 16-week CureSight treatment (P < 0.05). Cost per stereoacuity gain for 12-week treatment duration was $6421/log arcsec (glasses), $1801/log arcsec (patching), and $3007/log arcsec or $3488/log arcsec (CureSight). CONCLUSIONS: Treatment of amblyopia with Luminopia or CureSight is cost-effective in comparison with established willingness-to-pay thresholds and can provide a viable treatment option, especially for those who are unable to tolerate patching or atropine penalization. Cost-effectiveness values based on VA gain of Luminopia and CureSight were comparable. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
引用
- Koc I, Bagheri S, Chau RK, et al. Cost-effectiveness Analysis of Digital Therapeutics for Amblyopia. Ophthalmology. 2025. PMID: 39756692. doi:10.1016/j.ophtha.2024.12.037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。